Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score
- Product
- bosakitug (ATI-045)
- Milestone
- topline data
- Indication
- atopic dermatitis
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The failure to meet primary and secondary endpoints is expected to depress the stock, though the company highlights continued pipeline activity and upcoming trials for other assets.
Market read
First disclosure of a missed primary endpoint for a biotech trial; likely triggers short‑term sell‑off in ACRS.
What to watch
The company is shifting focus to oral kinase inhibitors and a bispecific antibody, which could mitigate the negative impact.
Background
Aclaris Therapeutics (NASDAQ: ACRS) is a clinical‑stage biopharma developing immuno‑inflammatory therapies. The ADMIRATION trial evaluated bosakitug (ATI‑045) in moderate‑to‑severe atopic dermatitis.
Ticker impact
Aclaris Therapeutics disclosed top‑line Phase 2 results showing its anti‑TSLP antibody bosakitug missed primary and secondary endpoints in atopic dermatitis.
downward pressure as investors price in the missed endpoints
Phase‑2 failure is material for a clinical‑stage biotech; market typically reacts negatively to missed primary endpoints.
Market effects
May dampen sentiment for other atopic dermatitis and TSLP‑targeted programs.
Limited to US‑listed biotech sector.
Low; impact confined to niche immunology biotech space.
Counterpoint
Management emphasizes robust target engagement and pipeline progress, suggesting long‑term upside despite this setback.
Key entities
- companyAclaris Therapeutics, Inc.
NASDAQ‑listed biotech reporting Phase 2 trial results.
- drug_candidateBosakitug (ATI‑045)
Anti‑TSLP monoclonal antibody tested in atopic dermatitis.

